- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ariatti joins Toshiba as marketing VP
Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at
Toshiba America Medical Systems has named John Ariatti as vicepresident of marketing to replace Ravi Sharma, who left the Tustin,CA, firm in July (SCAN 8/2/95). Ariatti is a medical imaging veteranwho previously was director of sales and marketing at Otsuka Electronicsand then at Elscint after that company acquired Otsuka last year.
Ariatti rejoins Toshiba after a stint with the vendor beginningin 1989, when he served as director of the CT business unit andlater as director of MRI marketing. He has also worked with PhilipsMedical Systems.
In his new position, Ariatti oversees marketing for Toshiba'sCT, MRI, nuclear medicine, and vascular and general x-ray products,as well as corporate marketing and marketing communications.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
